Diligence memo · auto-generated · as of July 2, 2026
Stipple Bio, Inc.
Stipple Bio, Inc. looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
Stipple Bio, Inc. operates in Biotechnology, based in Cambridge.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Stipple Bio, Inc. has raised $21M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $12M on 2022-05-31.
Most recent recorded round closed around 2024-12-20.
Valuation (modeled)modeled
Provath models Stipple Bio, Inc. at approximately $40M (range $10M–$77M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.89× the median modeled value of Series A Biotechnology companies in 2022–2024 (303 peers) — value vs value, same stage and era. Within the normal band (89% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 31 months.
Last raise 18 mo ago; this sector typically re-raises about every 14 months.
Slightly overdue versus sector cadence.
The last round was 1.3× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 69% of Biotechnology peers (4293 compared).
Modeled value ranks above 40% of those peers.
Closest niche peers: GeoVax Labs, Inc., Cellinfinity Bio Holding Company, LLC, Adient Medical, Inc., Entegrion Inc, BCD Bioscience, Inc..
Peoplefiled
5 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.